Analysis of US, Canadian and French mortality data shows lower death rates for COPD and asthma in France and dissimilar patterns by sex among these countries. The proportion of deaths from bronchitis was higher in France, while an increased use of generalized terms for COPD in death certificates was observed in Canada and the US. [...]

Continue reading " Mortality from Chronic Obstructive Pulmonary Diseases and Asthma in France: DISCUSSION "

COPD and asthma death rates from 1969 to 1983 for the three countries for the 65-74 years age group, the middle age-group of our study, are shown in Table 2. Intercountry comparisons for this age group typify comparisons for the other age groups. The proportion of COPD and asthma deaths due to bronchitis is much [...]

Continue reading " Mortality from Chronic Obstructive Pulmonary Diseases and Asthma in France: RESULTS "

Mortality data for COPD and asthma described in this study are from Vital Statistics of Canada, the US National Center for Health Statistics, L’Institut National de la Santё et de la Recherche Ntedicale for France, and issues of World Health Statistics Annual of the World Health Organization (WHO). Comparisons of death rates from 1969 to [...]

Continue reading " Mortality from Chronic Obstructive Pulmonary Diseases and Asthma in France: METHODS "

Respiratory diseases are among the leading causes of morbidity and mortality in many countries. Chronic obstructive pulmonary disease (COPD) is the most common respiratory cause of death and is mostly attributable to smoking. The mortality trend for COPD is of particular interest because, in the United States, and probably in other countries, trends are upward [...]

Continue reading " Mortality from Chronic Obstructive Pulmonary Diseases and Asthma in France "

It is also noteworthy that the iodinated glycerol- treated patients experienced a reduction in the dura­tion of acute exacerbations. These findings are consis­tent with other published studies which show that mucolytic therapy reduces both the severity and incidence of acute exacerbations and reduces the number of sick-day leaves in patients with chronic bronchitis. The purpose [...]

Continue reading " The National Mucolytic Study Results of a Randomized, Double-Blind, Placebo-Controlled Study off lodinated Glycerol: DISCUSSION part 2 "

At least 16 million Americans have chronic asthma, chronic bronchitis or emphysema alone or in combi­nation and this disease spectrum is commonly labeled COPD. The symptoms that accompany COPD are cough, expectoration, wheeze, and dyspnea, with varying degrees of severity. Cough and expectoration signify mucus in conducting air passages. Dyspnea is the symptomatic counterpart of [...]

Continue reading " The National Mucolytic Study Results of a Randomized, Double-Blind, Placebo-Controlled Study off lodinated Glycerol: DISCUSSION "

Determination of Responsive Groups Analyses Patients with moderate-to-severe symptoms for all scores at baseline: A group of moderately-to-severely symptomatic patients (n=107) who had a baseline (visit 1) symptom score of 3, 4, or 5 for all assessment parameters (cough frequency, cough severity, chest discomfort, difficulty in breathing, and aerosol bron-chodilator use) was analyzed. The analysis [...]

Continue reading " The National Mucolytic Study Results of a Randomized, Double-Blind, Placebo-Controlled Study off lodinated Glycerol: RESULTS continue "